Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat

The DOI matches its Crossref record; 36 of the 36 references it cites were found in a registry or an index.

Intravenous arketamine for treatment-resistant depression: open-label pilot study

Open access
Leal, Gustavo C., Bandeira, Igor D., Correia-Melo, Fernanda S., Telles, Manuela, Mello, Rodrigo P., Vieira, Flavia, Lima, Cassio S., Jesus-Nunes, Ana Paula, Guerreiro-Costa, Lívia N. F., Marback, Roberta F., Caliman-Fontes, Ana Teresa, Marques, Breno L. S., Bezerra, Marília L. O., Dias-Neto, Alberto L., Silva, Samantha S., Sampaio, Aline S., Sanacora, Gerard, Turecki, Gustavo, Loo, Colleen, Lacerda, Acioly L. T., Quarantini, Lucas C. · 2021 · European Archives of Psychiatry and Clinical Neuroscience

Abstract

We aimed to analyze the efficacy and safety of arketamine, the R(-)-enantiomer of ketamine, for treatment-resistant depression (TRD) in humans. Open-label pilot trial, seven subjects with TRD received a single intravenous infusion of arketamine (0.5 mg/kg); primary outcome was change in Montgomery-Åsberg Depression Rating Scale (MADRS) 24 h after. Mean MADRS dropped from 30.7 before infusion to 10.4 after one day, a mean difference of 20.3 points [CI 95% 13.6-27.0; p < 0.001]; dissociation was nearly absent. Arketamine might produce fast-onset and sustained antidepressant effects in humans with favorable safety profile, like previously reported with animals; further controlled-trials are needed.

Overview

Integrity signals

Registry

Crossref · 10.1007/s00406-020-01110-5

Cites

36 of 36 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 36 references

Cited by

See all 263

Metadata

Authors
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., Caliman-Fontes, A. T., Marques, B. L. S., Bezerra, M. L. O., Dias-Neto, A. L., Silva, S. S., Sampaio, A. S., Sanacora, G., Turecki, G., Loo, C., Lacerda, A. L. T., & Quarantini, L. C.
Affiliations
  • Universidade Federal da Bahia (BR)
  • Yale University (US)
  • Douglas Mental Health University Institute (CA)
  • Black Dog Institute (AU)
  • Universidade Federal de São Paulo (BR)
Corresponding author
Quarantini, Lucas C.
Venue
European Archives of Psychiatry and Clinical Neuroscience
Published
2020-02-20
Volume
271
Issue
3
Pages
577-582
ISSN
  • 0003-9373 (ISSN-L)
  • 0940-1334
  • 1433-8491
OpenAlex
W3007923795
Cited by
257
References
36
Citations by year
2026: 10 · 2025: 28 · 2024: 58 · 2023: 35 · 2022: 49 · 2021: 45 · 2020: 31
FWCI
24.12
Type
journal article
Language
en
Open access
Licence
Locations
  • European Archives of Psychiatry and Clinical Neuroscience (publishedVersion)
  • PubMed (publishedVersion)
  • UNSWorks (University of New South Wales, Sydney, Australia) (submittedVersion, cc-by-nc-nd)
Funders
Programa de Pesquisa para o SUS (003/2017)
Topics
  • Health Sciences › Medicine › Pharmacology (medical) › Treatment of Major Depression
  • Health Sciences › Medicine › Psychiatry and Mental health › Electroconvulsive Therapy Studies
  • Life Sciences › Neuroscience › Biological Psychiatry › Tryptophan and brain disorders
Keywords
ketamine enantiomers, treatment-resistant depression, intravenous infusion, antidepressant efficacy, dissociation, Montgomery-Asberg Depression Rating Scale, drug safety
MeSH terms
Adult, Aged, Antidepressive Agents, Depressive Disorder, Major, Major Depressive Disorder, Female, Humans, Infusions, Intravenous, Ketamine, Middle Aged, Pilot Projects, Psychiatric Status Rating Scales, Remission Induction, Severity of Illness Index, Outcome Assessment, Health Care, Depressive Disorder, Treatment-Resistant

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Intravenous arketamine for treatment-resistant depression: open-label pilot study. https://app.cochat.ai/papers/10.1007/s00406-020-01110-5
The paper
Leal, G. C., Bandeira, I. D., Correia-Melo, F. S., Telles, M., Mello, R. P., Vieira, F., Lima, C. S., Jesus-Nunes, A. P., Guerreiro-Costa, L. N. F., Marback, R. F., Caliman-Fontes, A. T., Marques, B. L. S., Bezerra, M. L. O., Dias-Neto, A. L., Silva, S. S., Sampaio, A. S., Sanacora, G., Turecki, G., Loo, C., . . . Quarantini, L. C. (2021). Intravenous arketamine for treatment-resistant depression: open-label pilot study. European Archives of Psychiatry and Clinical Neuroscience. https://doi.org/10.1007/s00406-020-01110-5

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.